Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-cancer Agents

2020 ◽  
Vol 20 ◽  
Author(s):  
Ruo-Jun Man ◽  
Nasreen Jeelani ◽  
Chongchen Zhou ◽  
Yu-Shun Yang
Keyword(s):  
Clinical Trials ◽  
Anticancer Agents ◽  
Rational Design ◽  
Biological Macromolecules ◽  
Quinoline Derivatives ◽  
Specific Topic ◽  
Anti Cancer ◽  
The World ◽  
New Challenges ◽  
The Relationship

Background: Along with the progress in medicine and therapies, the exploitation of anti-cancer agents focused more on the vital signaling pathways and key biological macromolecules. With rational design and advanced synthesis, quinoline derivatives have been utilized frequently in medicinal chemistry, especially in developing anti-cancer drugs or candidates. Methods: Using DOI searching, articles published before 2020 all over the world have been reviewed as comprehensively as possible. Results: In this review, we selected the representative quinoline derivate drugs in market or clinical trials, classified them into five major categories with detailed targets according to their main mechanisms, discussed the relationship within the same mechanism, and generated a summative discussion with prospective expectations. For each mechanism, the introduction of the target was presented, with the typical examples of quinoline derivate drugs. Conclusion: This review has highlighted the quinoline drugs or candidates, suited them into corresponding targets in their pathways, summarized and discussed. We hope that this review may help the researchers who are interested in discovering quinoline derivate anticancer agents obtain considerable understanding in this specific topic. Through the flourishing period and the vigorous strategies in clinical trials, quinoline drugs would be potential but facing new challenges in future.

scholarly journals Anticancer Agents from Diverse Natural Sources

2014 ◽  
Vol 9 (11) ◽  
pp. 1934578X1400901 ◽  
Author(s):  
Jabeena Khazir ◽  
Darren L. Riley ◽  
Lynne A. Pilcher ◽  
Pieter De-Maayer ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Anticancer Agents ◽  
Marine Organisms ◽  
New Drugs ◽  
Human Diseases ◽  
Cancer Drugs ◽  
Natural Sources ◽  
Anti Cancer ◽  
Ancient Times

This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.

Development of ruthenium-based complexes as anticancer agents: toward a rational design of alternative receptor targets

2016 ◽  
Vol 36 (2) ◽  
Author(s):  
Adebayo A. Adeniyi ◽  
Peter A. Ajibade
Keyword(s):  
Clinical Trials ◽  
Side Effects ◽  
Anticancer Agents ◽  
Rational Design ◽  
Coordination Complexes ◽  
Future Prospects ◽  
Phase Ii Clinical Trials ◽  
Ru Complexes ◽  
Receptor Targets ◽  
Therapeutic Activities

AbstractIn the search for novel anticancer agents, the development of metal-based complexes that could serve as alternatives to cisplatin and its derivatives has received considerable attention in recent years. This becomes necessary because, at present, cisplatin and its derivatives are the only coordination complexes being used as anticancer agents in spite of inherent serious side effects and their limitation against metastasized platinum-resistant cancer cells. Although many metal ions have been considered as possible alternatives to cisplatin, the most promising are ruthenium (Ru) complexes and two Ru compounds, KP1019 and NAMI-A, which are currently in phase II clinical trials. The major obstacle against the rational design of these compounds is the fact that their mode of action in relation to their therapeutic activities and selectivity is not fully understood. There is an urgent need to develop novel metal-based anticancer agents, especially Ru-based compounds, with known mechanism of actions, probable targets, and pharmacodynamic activity. In this paper, we review the current efforts in developing metal-based anticancer agents based on promising Ru complexes and the development of compounds targeting receptors and then examine the future prospects.

Terror, Race, Security

2018 ◽  
Author(s):  
Yulia Egorova
Keyword(s):  
Jewish Identity ◽  
War On Terror ◽  
Jewish Communities ◽  
Security Issues ◽  
Caste Discrimination ◽  
The World ◽  
New Challenges ◽  
Muslim Communities ◽  
The Relationship ◽  
State Of Israel

The chapter engages with the two main themes of the book by focusing on the way in India the relationship between Jews and Muslims and imageries of Jewish and Muslim communities became affected by the Mumbai attacks and the general post 9/11 rhetoric of the “war on terror.” The chapter shows that these events and the securitization discourses that emerged in their aftermath created new challenges for local Jewish and Muslims groups, but it also complicates accounts that reduce Jewish-Muslim relations to problems of security. The ethnographic examples presented in this chapter suggest that concerns about the perceived Muslim threat that some of the Jewish respondents exhibited in relation to Indian Muslims ultimately had very little to do with Islam and were embedded in the wider problematics of security issues facing Jewish communities around the world, the politics of Jewish identity arbitration in the State of Israel, and even the reality of caste discrimination in India.

Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents

2020 ◽  
Vol 27 (15) ◽  
pp. 2449-2493 ◽  
Author(s):  
Loredana Cappellacci ◽  
Diego R. Perinelli ◽  
Filippo Maggi ◽  
Mario Grifantini ◽  
Riccardo Petrelli
Keyword(s):  
Clinical Trials ◽  
Histone Deacetylase ◽  
Anticancer Agents ◽  
Histone Deacetylase Inhibitors ◽  
Cyclic Peptide ◽  
Hdac Inhibitors ◽  
Cancer Therapeutics ◽  
Rational Drug Design ◽  
Modeling Tools ◽  
Anti Cancer

Histone Deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval by the FDA of four HDAC inhibitors, vorinostat, romidepsin, belinostat and panobinostat, used for the treatment of cutaneous/peripheral T-cell lymphoma and multiple myeloma. Many more HDAC inhibitors are at different stages of clinical development for the treatment of hematological malignancies as well as solid tumors. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. In the intensifying efforts to discover new, hopefully, more therapeutically efficacious HDAC inhibitors, molecular modelingbased rational drug design has played an important role. In this review, we summarize four major structural classes of HDAC inhibitors (hydroxamic acid derivatives, aminobenzamide, cyclic peptide and short-chain fatty acids) that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.

A ma és a holnap teológiai képzése

2019 ◽  
Vol 22 (1) ◽  
pp. 7-31
Author(s):  
Attila Bodor
Keyword(s):  
High Education ◽  
Theological Education ◽  
Tertiary Education ◽  
Pastoral Work ◽  
The World ◽  
New Challenges ◽  
The Relationship ◽  
Changing World

The world has changed in many aspects in recent decades, and this has impacted on high education too. Theological faculties as parts of tertiary education need to face new challenges created by the postmodern society. The present study addresses this issue by presenting both the major challenges and the possible solutions of how to overcome them. In my view, the challenges faced by theological faculties are basically three: the relationship between theology and sciences, the place of theology as a discipline at the universities, and the role of theology in pastoral work. It will be argued that to answer the challenges posed by the changing world, theological education should be interdisciplinary, contextual, and authentic. In other terms, it should engage in dialogue with other disciplines and society while remaining faithful to its historical roots.

Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis

2021 ◽  
Vol 10 (2) ◽  
pp. 73-82
Author(s):  
Hai-Long Zhang ◽  
Yiqian Li
Keyword(s):  
Anticancer Agents ◽  
Antineoplastic Agents ◽  
Public Health Problem ◽  
Comprehensive Analysis ◽  
Major Public Health Problem ◽  
Anti Cancer ◽  
Recent Developments ◽  
New Evidence ◽  
The Relationship

Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents, and to better demonstrate recent developments for patents concerning drugs for osteoporosis, we conducted an analysis of US patents. The results indicated that there was a good correlation between agents for osteoporosis and antineoplastic agents, which indicated that numerous anti-osteoporosis agents displayed antineoplastic activities. Our study was the first one to provide new evidence, through comprehensive analysis, for a correlation between anti-osteoporosis agents and anticancer agents. The present study may open new avenues for developing anticancer drugs and expanding the application role of anti-osteoporosis agents.

Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology

2007 ◽  
Vol 25 (29) ◽  
pp. 4642-4647 ◽  
Author(s):  
Rachel P. Riechelmann ◽  
Lisa Wang ◽  
Aoife O'Carroll ◽  
Monika K. Krzyzanowska
Keyword(s):  
Clinical Trials ◽  
North America ◽  
Anticancer Agents ◽  
Conflicts Of Interest ◽  
Multivariable Analysis ◽  
Cross Sectional Survey ◽  
Clinical Cancer Research ◽  
Cross Sectional ◽  
The Relationship ◽  
North America North

Purpose There is concern that financial relationships between sponsors and investigators may bias research results. Our objective was to evaluate the epidemiology of conflicts of interest (COIs) among authors of clinical trials and editorials in oncology and the relationship between COI disclosure and source of funding. Methods We did a cross-sectional survey of clinical trials and editorials of anticancer agents and supportive care medications published in the Journal of Clinical Oncology (JCO) during a 1-year period. Results Of 1,533 articles published in JCO between January 1, 2005, and January 31, 2006, 332 met our inclusion criteria; 289 (87%) were clinical trials, and 43 (13%) were editorials. The pharmaceutical industry entirely or partially funded 44% of the clinical trials. At least one COI was disclosed in 69% of clinical trials and 51% of editorials. The most common types of COI reported by authors were consultancy fees, honoraria, and research funds. The highest monetary levels of interest reported by authors were for research grants, but the majority of authors with COIs received less than US$10,000. In multivariable analysis, authors of clinical trials conducted in North America (North America v Europe: odds ratio [OR] = 2.9, P = .002) and authors of trials funded entirely (industry only v nonprofit: OR = 13.8, P < .001) or partially (both industry and nonprofit v nonprofit only: OR = 5.8, P < .001) by industry were more likely to report personal COIs. Conclusion COIs are common in clinical cancer research and usually take the form of consultancy fees, honoraria, and research funds. Source of study funding was significantly associated with COI disclosure.

The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests

2019 ◽  
Vol 19 (4) ◽  
pp. 277-284
Author(s):  
Jie Wang ◽  
Haiyan Dong ◽  
Jian Liu ◽  
Ning Zheng ◽  
Xiaodong Xie ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Anticancer Drugs ◽  
Anticancer Agents ◽  
Drug Effects ◽  
Relevant Information ◽  
Clinical Tests ◽  
Toxicological Studies ◽  
Anti Cancer ◽  
Online Sources

Background: One of the main reasons for most of the anticancer drugs to fail in the late preclinical testing and early clinical trials is the differences in drug effects observed from animals and patients, and the challenge has been to find a balance to reduce the inherent differences from species. Objective: Predicting safe starting doses and dosing schedules for human clinical trials is the main purpose of toxicological studies of anticancer drugs. Methods: Relevant information and data were assimilated from manuscripts, congress publications, and online sources. Results: We systematically overview the cons and pros of animal models and briefed the ways to determine human clinical starting doses derived from animal toxicological studies for anticancer drugs. Conclusion: This information helps smart select the suitable predictive model for anti-cancer drugs with the different mechanisms and emphasized the pharmaceutical challenges behind and ahead.

scholarly journals Environmental Concerns of the Pulp and Paper Industry: Focusing on Household and Sanitary Paper Products

2021 ◽  
pp. 181-195
Author(s):  
Kun Qian
Keyword(s):  
Paper Industry ◽  
Pulp And Paper Industry ◽  
Pulp And Paper ◽  
Environmental Concerns ◽  
Retail Market ◽  
Daily Lives ◽  
The World ◽  
Sanitary Products ◽  
New Challenges ◽  
The Relationship

AbstractThe category of household and sanitary products is the most important category in the paper industry, because it is related to people’s daily lives all around the world. This category is seeing a rapid increase in consumption, while consumption in other categories, such as printing or writing paper, is presently declining. China is the largest manufacturer, as well as the largest consumer of household and sanitary paper. Nowadays, environmental consciousness and concerns are rising in China and have started to influence customers’ behavior in selecting and using paper products. In the present study, surveys were conducted of the paper industry, the retail market for paper, and end consumers of paper. The relationship between new challenges of the paper industry and consumers’ environmental concerns has been investigated and reported.

scholarly journals Preventive effects of statins on the incidence of liver cancer

2018 ◽  
Vol 5 (3) ◽  
pp. 2130-2132
Author(s):  
Hamid Salehiniya ◽  
Khadijah Allah Bakeshei ◽  
Abdollah Mohammadian-Hafshejani
Keyword(s):  
Clinical Trials ◽  
Liver Cancer ◽  
Heart Attack ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Protective Effects ◽  
The World ◽  
The Relationship ◽  
Preventive Effects ◽  
Very High

Liver cancer is considered as one of the most common cancers in the world, so that it is ranked fifth in males and sixth in females in the world causing high annual costs to patients, the health system and society (Ferlay et al., 2015). The worldwide mortality rate of this disease is rising annually. This disease also has a very high fatality, so that 88% of patients in USA (Miller et al., 2016) and 90% of patients in China (Zeng et al., 2015) die of this disease in the first 5 years of its diagnosis. Therefore, it is essential to identify factors which protect against this disease. The protective effects of Statins against the cardiovascular diseases, stroke and heart attack has been proven (Tobert, 1996). Recent studies have found that Statins can also have protective effects against the cancers (Yi, Song, Wan, Chen, & Cheng, 2017). Several meta-analysis studies have explored the relationship between Statin receiving and the risk of developing liver cancer by application of randomized clinical trials, and found that the use of Statins significantly reduces the risk of liver cancer.

Sign in / Sign up

Export Citation Format

Share Document